Plain-English translation of NCT07166601 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study of a new medication called , which is designed to help your immune system fight cancer cells. Researchers will test whether this medication works best on its own, combined with an immune-boosting drug called , or combined with chemotherapy. The main goal is to find a safe and effective dose for future, larger studies.
Many patients with advanced cancers stop responding to standard treatments, and doctors need new options. This medication targets cancer cells in a new way, and this study will determine whether it's safe and whether it shows promise in helping patients whose cancers have become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an infusion (injection into your vein) at a research clinic, likely on a regular schedule. Depending on which group you join, you may receive this medication alone or combined with other cancer treatments. You will have regular blood tests, physical exams, and imaging scans to check how well the treatment is working and to monitor for side effects. The study will track your health and response to treatment over time.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Canada
Japan